Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Apr 26 LNTH Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
Apr 26 EXEL Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
Apr 26 EXEL Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Apr 25 CRDF Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Apr 25 VERU Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
Apr 25 ACHV Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
Apr 25 XOMA XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Apr 24 LNTH Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know
Apr 24 LNTH Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know
Apr 24 NUVB Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 24 XOMA Actym Therapeutics Appoints Thomas Smart as CEO
Apr 24 INO Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation
Apr 23 XOMA Day One wins FDA nod for brain cancer therapy, Ojemda
Apr 23 LNTH Why Lantheus Holdings (LNTH) is a Top Growth Stock for the Long-Term
Apr 23 INO Inovio Pharmaceuticals: The Dilution Continues
Apr 23 EDAP EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
Apr 22 LNTH How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Apr 20 XOMA XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags